Pharco intends to be among the best generic manufacturers in the world — judged on quality, on cost, and on getting there first.
Products developed in-house
Bioequivalence studies completed
Markets registered
Patients cured of hepatitis C
API manufacturing at PBIC
Finished dosage form lines
Every product built to the toughest regulator that will see it. Quality by Design and AI-assisted development give us a working model of how each formulation behaves, so target attributes are met by design and stability holds to the last day of shelf life.
The region's largest pharmaceutical manufacturer by volume — scale that shows in every input we buy. Most active ingredients come from India and China, where that scale is greatest. We make our own at PBIC when they cannot be bought: patented in India and China but not in Egypt, novel to us, or needing a non-infringing route of synthesis.
First-wave filings. Development, bioequivalence and regulatory strategy run in parallel, supported by our own regulatory intelligence and dossier systems.
Pharco made the active ingredient, developed the product, registered it and manufactured at a scale that removed most of the cost. More than four million Egyptians were cured. In 2023 Egypt became the first country awarded WHO gold tier status on the path to hepatitis C elimination; WHO credited locally manufactured antivirals.
Ravidasvir went further: a new chemical entity developed with DNDi, Médecins Sans Frontières, Pharmaniaga and Malaysia's Ministry of Health, and the first hepatitis C treatment created through South-South collaboration. 97% cure rate. Approved in Egypt, Malaysia and Thailand, with further registrations under way, and on the WHO Essential Medicines List since 2023. Pharco acquired Presidio Pharmaceuticals and owns the molecule. Licences cover 139 countries.
We are not a discovery house. But when the market will not solve a health problem, we can.
One connected chain: active ingredient, formulation, bioequivalence, dossier. Solid orals, sterile injectables and, increasingly, peptides and biosimilars.
Route development, scale-up and DMF preparation at PBIC, built by European contractors and state of the art from day one. EDA-approved, WHO-prequalified, ANVISA-approved.
Solid oral dosage, sterile injectables, biosimilar fill-finish, herbal and nutraceutical. Design space defined before the first pilot batch.
Development equipment mirrors commercial production. Fewer pilot campaigns, fewer failed exhibit batches, faster scale-up.
Methods developed and validated to ICH. Full ICH Zone IVb stability programmes for our Malaysian and Latin American markets.
More than 300 bioequivalence studies. International trial experience through ravidasvir.
CTD and eCTD dossiers approved in more than 60 markets: NPRA Malaysia, ANVISA Brazil, Saudi FDA, GCC, the European Union via Romania, TMDA Tanzania, WHO prequalification.
Every collaboration has a defined scientific objective.
Co-development, trials, funding and registration of ravidasvir with sofosbuvir for countries running elimination campaigns.
Plant-derived anticancer candidate.
Process and manufacturing collaboration on the ravidasvir and sofosbuvir active ingredients.
To discuss a research collaboration, a licensing opportunity or a development partnership, contact our Business Development team at Portfolio@pharco-corp.com.